MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Rechargeable pacemaker technology in deep brain stimulation: A step forward, but nor for everyone

J. Runge, A. Wloch, M. Abdallad, M. Manu, J.K. Krauss (Hannover, Germany)

Meeting: 2016 International Congress

Abstract Number: 34

Keywords: Deep brain stimulation (DBS)

Session Information

Date: Monday, June 20, 2016

Session Title: Surgical therapy: Parkinson's disease

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: Since a few years rechargeable pacemaker technology is available in deep brain stimulation. This technical innovation becomes more and more important in clinical practice, particularly for patients with a need for high energy delivery. Unforeseen handling issues, however, may compromise its use in certain patients.

Methods: Over a period of ten years, 360 patients underwent deep brain stimulation for various indications. Rechargeable pacemakers are increasingly used upon replacement after battery depletion. Despite meticulous screening for suitability, we had to switch battery to non-rechargeable technology because of unforeseen technical difficulties in two patients.

Results: A 73-year-old man with a high cognitive performance with Parkinson’s disease, underwent bilateral deep brain stimulation in the internal globus pallidus. Pulse generators were replaced because of battery depletion in 2-year intervals. At the time of third replacement, it was decided to use rechargeable technology because of the relatively frequent need of pacemaker replacements. Two years later the patient requested to remove the pacemaker and reimplant a non-rechargeable once more because of increasing problems with handling of the recharger and inconvenience with the daily monitoring of the battery level. A 62-year-old woman underwent bilateral deep brain stimulation in the nucleus accumbens for alcohol addiction. She needed biennial pacemaker replacements, the pacemaker was replaced against a rechargeable device at the time of the second replacement. Two years later system malfunction was detected with fracture of the extension cable secondary to twiddler’s syndrome. The patient for the main part had had increased difficulties recharging the battery.

Conclusions: Rechargeable pacemaker undoubtedly are a step forward in providing standard of care medical treatment. Many patients stand to benefit from rechargeable technology, smaller devices and fewer replacement operations. However, with new technology we also have new requirements concerning technical capabilities and compliance. Although removal of a rechargeable device before end of service of the battery and replacement with a non-rechargeable pacemaker poses an undue economic burden, it may be the only solution under certain circumstances to guarantee the benefit of chronic stimulation.

To cite this abstract in AMA style:

J. Runge, A. Wloch, M. Abdallad, M. Manu, J.K. Krauss. Rechargeable pacemaker technology in deep brain stimulation: A step forward, but nor for everyone [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/rechargeable-pacemaker-technology-in-deep-brain-stimulation-a-step-forward-but-nor-for-everyone/. Accessed June 10, 2026.
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/rechargeable-pacemaker-technology-in-deep-brain-stimulation-a-step-forward-but-nor-for-everyone/

Most Viewed Abstracts

  • This Month
  • All Time
  • #24475 (not found)
  • Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley